These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 10147230)

  • 1. Statistical versus quantitative significance in the socioeconomic evaluation of medicines.
    O'Brien BJ; Drummond MF
    Pharmacoeconomics; 1994 May; 5(5):389-98. PubMed ID: 10147230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical importance, statistical significance and the assessment of economic and quality-of-life outcomes.
    Drummond M; O'Brien B
    Health Econ; 1993 Oct; 2(3):205-12. PubMed ID: 8275165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of randomised controlled trials for producing cost-effectiveness evidence: potential impact of design choices on sample size and study duration.
    Backhouse ME
    Pharmacoeconomics; 2002; 20(15):1061-77. PubMed ID: 12456201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life assessment and the pharmaceutical industry.
    Revicki DA; Rothman M; Luce B
    Pharmacoeconomics; 1992 Jun; 1(6):394-408. PubMed ID: 10147021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
    Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
    Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness as an outcome in randomized clinical trials.
    Hlatky MA; Owens DK; Sanders GD
    Clin Trials; 2006; 3(6):543-51. PubMed ID: 17170039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-per-QALY league tables: their role in pharmacoeconomic analysis.
    Mason JM
    Pharmacoeconomics; 1994 Jun; 5(6):472-81. PubMed ID: 10147264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters.
    Hoch JS; Dewa CS
    Pharmacoeconomics; 2007; 25(10):807-16. PubMed ID: 17887803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Educational interventions to improve quality of life in people with chronic inflammatory skin diseases: systematic reviews of clinical effectiveness and cost-effectiveness.
    Pickett K; Loveman E; Kalita N; Frampton GK; Jones J
    Health Technol Assess; 2015 Oct; 19(86):1-176, v-vi. PubMed ID: 26502807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Endovascular Stroke Therapy: A Patient Subgroup Analysis From a US Healthcare Perspective.
    Kunz WG; Hunink MG; Sommer WH; Beyer SE; Meinel FG; Dorn F; Wirth S; Reiser MF; Ertl-Wagner B; Thierfelder KM
    Stroke; 2016 Nov; 47(11):2797-2804. PubMed ID: 27758942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stochastic league tables: an application to diabetes interventions in the Netherlands.
    Hutubessy RC; Niessen LW; Dijkstra RF; Casparie TF; Rutten FF
    Health Econ; 2005 May; 14(5):445-55. PubMed ID: 15386648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health economic evaluation of moist wound care in chronic cutaneous leishmaniasis ulcers in Afghanistan.
    Stahl HC; Ahmadi F; Nahzat SM; Dong HJ; Stahl KW; Sauerborn R
    Infect Dis Poverty; 2018 Feb; 7(1):12. PubMed ID: 29444705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methodological design for economic evaluation in Public Access Defibrillation (PAD) trial.
    Nichol G; Wells GA; Kuntz K; Feeny D; Longstreth W; Mahoney B; Mann C; Lucas R; Henry M; Huszti E; Birnbaum A
    Am Heart J; 2005 Aug; 150(2):202-8. PubMed ID: 16086918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.
    Lipsy RJ
    Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply to Coyle's comments on 'uncertainty in cost-effectiveness analysis: probabilistic uncertainty analysis and stochastic league tables'.
    Baltussen RM; Hutubessy RC; Evans DB; Murray CJ
    Int J Technol Assess Health Care; 2003; 19(4):682-4. PubMed ID: 15095773
    [No Abstract]   [Full Text] [Related]  

  • 19. Economic endpoints in clinical trials.
    Hlatky MA
    Epidemiol Rev; 2002; 24(1):80-4. PubMed ID: 12119860
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.